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Guest Editorial
Beta-blockers: A Second Rate Treatment for Hypertension?
BERNARD M Y CHEUNG
From Department of Medicine and Research Centre of Heart, Brain, Hormone and Healthy Aging, The University of
Hong Kong, Queen Mary Hospital, Hong Kong SAR

Hypertension is a major risk factor for stroke and
myocardial infarction. Lowering blood pressure by
5-6 mmHg reduces the stroke risk by 38%. 1 It is
astonishing that the treatment of hypertension is so
beneficial when the efficacy of currently available
antihypertensive drugs is so modest. Thus, any drug,
which lowers blood pressure and is safe, is approved
for clinical use. In the last decade, large clinical trials
have been conducted to compare antihypertensive drugs
in terms of cardiovascular outcome.2,3 One of the latest
trials was the Anglo-Scandinavian Cardiac Outcomes
Trial (ASCOT), the results of the blood pressure
lowering arm of which have recently been reported at
the American College of Cardiology Annual Scientific
Session.4 The database is not complete yet, but the
preliminary results already show that the amlodipineperindopril arm (new drugs) had better outcomes than
the diuretic-beta-blocker arm (old drugs). Furthermore,
there were more new cases of diabetes in the latter arm.
The results of ASCOT were unexpected, because
previous trials of old versus new drugs had been a tie.5-7 In
the Antihypertensive and Lipid-Lowering Treatment to
Prevent Heart Attack Trial (ALLHAT), 8 diuretics
performed as well as amlodipine and lisinopril, but
because thiazide diuretics have been in use for a long
time and are economical, they are promoted as first line
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treatment in the Seventh Report of the Joint National
Committee on Prevention, Detection, Evaluation, and
Treatment of High Blood Pressure (JNC7).9 However,
beta-blockers are not advocated as first line treatment
in JNC7. In the British guidelines, there are explicit
reservations regarding beta-blockers.10 In older trials on
hypertension, beta-blockers were used together with
thiazide diuretics and so took a share of the credit for
the benefits shown.1 On their own, they are less than
impressive.11 In the Medical Research Council trial of
treatment of hypertension in older adults, beta-blockers
were no better than placebo and significantly inferior to
diuretics.12 In the Losartan Intervention For Endpoint
reduction in hypertension study (LIFE), atenolol was
inferior to losartan with regard to stroke, although it was
non-significantly better than losartan in terms of
myocardial infarction.13 A recent meta-analysis showed
that atenolol performs consistently less well than other
antihypertensive drugs in clinical trials.14
ASCOT was an unequal race between old warhorses and young thoroughbreds. Diuretics and betablockers need to be used at low doses, limiting their
blood pressure lowering effect. These drugs also
worsen the metabolic profile whereas angiotensinconverting enzyme inhibition prevents diabetes. 15
Amlodipine is a very efficacious antihypertensive
agent.16,17 Small differences in blood pressure control
can be translated to significant differences in clinical
outcome, as in the Valsartan Antihypertensive Longterm Use Evaluation (VALUE) trial.18,19 Amlodipine
also has an anti-atherosclerotic effect in carotid and
coronary arteries.20,21
Beta-blockers remain valuable in the treatment
of angina pectoris and myocardial infarction, and their
use in heart failure clearly reduces mortality.22 They are
contraindicated in asthma and peripheral vascular
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disease. In the light of the latest evidence, the use of a
beta-blocker should not be a reflex but a carefully
considered action. The American and World Health
Organization guidelines may require revision, 9,23
whereas the European guidelines characteristically give
equal weight to each antihypertensive drug class.24 The
British guidelines hold up rather well.10 The British
Hypertension Society, adopting the Cambridge ABCD
rule, proposes that beta-blockers are less suitable as firstline treatment in the elderly.25 I would not discard them
for the moment, not least because they are surprisingly
the best tolerated antihypertensive drug class apart from
angiotensin receptor blockers.26 The majority of patients
require a number of drugs to reach current blood pressure
targets (140/90 mmHg and lower targets for patients with
diabetes or nephropathy).9,10,23,24 Beta-blockers may
therefore be one of the drugs used to attain good blood
pressure control. 27 Drug companies are keen to
emphasise and exploit small differences between drugs,
but these pale into insignificance when compared to the
paramount importance of good blood pressure control.
Beta-blockers are out of favour for hypertension for the
moment, but the full results of ASCOT are still awaited.
The pendulum may swing this way and that way from
time to time, but it will finally come to rest in the middle.
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Exercise Habit of Cardiac Patients after Phase II Cardiac
Rehabilitation Programme
WINSOME YEE-MAN MAK,1 WAI-KWONG CHAN,1 SUNNY CHIU-SUN YUE,1 ELEANOR YEE WONG
CHAN,2 ERIC SIN-WING WONG2
From 1Division of Cardiology, 2Physiotherapy Department, United Christian Hospital, Hong Kong SAR
MAK ET AL.: Exercise Habit of Cardiac Patients after Phase II Cardiac Rehabilitation Programme. Objectives:
To determine the exercise habit of patients who completed Phase II cardiac rehabilitation programme (CRP)
from July 2002 to October 2003. Methods: Phone survey was conducted with patients who self-reported their
exercise pattern. Type, frequency, duration, and intensity of exercise; exercise tolerance (ET) in terms of flight
of stairs (FOS) achieved and walking distance on level ground, and pre-programme exercise habit were analysed.
Results: Among 120 Phase II graduates, 107 patients responded to the survey. Ninety-five patients (70 males),
aged 45-82, reported they did exercise weekly. Forty-six patients (48.4%) did not exercise regularly beforehand.
Walking was the most common exercise (66.3%). Light and moderate to vigorous-intensity exercises were
performed by 47% and 53% of patients respectively. Exercise <3 times/week or spent <30 minutes/session was
revealed in 27% of patients. Frequency and duration of exercise were not statistically different between male
and female patients. However, patients ≥65 years did exercise more often than their younger counterparts (p=
0.018). Regarding ET, 60% and 63% of patients reported that they could walk for >1 hour on level ground and
climb ≥6 FOS at a time respectively. Conclusions: Most patients (88.8%) could achieve regular exercise habit
after completion of Phase II CRP. However, more than 25% of patients did not practice exercise accordingly to
the exercise guidelines. Education and counselling in long-term maintenance of exercise with appropriate
frequency, duration and intensity should be emphasised. (J HK Coll Cardiol 2005;13:4-9)
Cardiac rehabilitation, exercise
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Introduction
Regular exercise is one of the risk-reduction
interventions in cardiac rehabilitation.1 It improves
atherosclerotic risk factors, reduces cardiac mortality,
and decreases symptoms development in patients with
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coronary artery disease (CAD).2-4 On completion of
Phase II training, exercise prescriptions and the
importance of continuing regular exercise are given to
patients by physiotherapists. The purpose of this study
was to determine the exercise habit of cardiac patients
following their completion of Phase II cardiac
rehabilitation programme (CRP).

Methods
Subjects
Cardiac patients who completed Phase II CRP
in United Christian Hospital during the period from
July 2002 to October 2003 were included in this
study.

achieved and walking distance on level ground, and
exercise habit before Phase II training were used to
measured patients' exercise pattern. In evaluation of FOS
achieved, a fight of stairs was regarded as 10 steps.5

Survey Form
The phone survey was conducted in early March
2004. Questionnaire consisted of eight questions was
used to explore and record patients' exercise pattern
(Figure 1). Patients self-reported their current exercise
pattern. Their replies were then categorized and analysed
accordingly. Types of exercise performed by patients
were classified into light (<3 metabolic equivalents,
METs), moderate (3-6 METs), and vigorous intensity
(>6 METs).6

Results

Outcome Measures
Parameters including type, frequency, duration,
and intensity of exercise performed by patients, exercise
tolerance (ET) in terms of flights of stairs (FOS)

One hundred and twenty patients completed
Phase II CRP during the period from July 2002 to

Figure 1. Survey form for assessment of patients' exercise habit after completion of Phase II CRP.
J HK Coll Cardiol, Vol 13
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October 2003. There were 86 males and 34 females,
their age ranged from 43 to 82 years old. By the time of
the study, they were discharged five to twenty months
from Phase II training. Thirteen patients' data were not
available due to death in four, refusal to study in one,
and inability to contact in eight patients.

Non-Exercise Group
Out of 107 patients who responded to the survey,
12 patients (11.2%) did not exercise. There were 6 males
and 6 females, age ranged from 43 to 80 years. Major
barriers including injuries and pain over body parts,
recent medical events, time constraints, and forgot own
exercise prescription were reported in five, three, three,
and one patients respectively.

Patients' Exercise Pattern
1. Types and Intensity
Walking was the most common type of exercise
practiced by 66.3% of patients, followed by Chinese
Wushu for example Tai Chi and Qigong, and stretching
by 24.2%, and 11.6% of patients. Other types of exercise
including swimming, playing ball games, cycling and
hiking were also done by patients (Figure 2). Out of
those 95 patients, three patients did exercise at
community or sports centres. All patients created their
own exercise programme. Fifty-five patients (47%)
performed light-intensity exercises, the rest (53%)
worked out at moderate to vigorous level (Figure 3).

2. Frequency and Duration
Exercise Group
Ninety-five patients (88.8%) reported that they
did exercise after Phase II training. There were 70 males
and 25 females, their mean age was 65.1±9.0 (range
45-82) years. Fifty-four patients (56.8%) were aged over
65. Among 95 patients, 48.4% of patients developed
exercise habit following Phase II CRP.

Thirteen patients (13.7%) did exercise <3 times/
week, while 61 patients (64.2%) of patients did exercise
almost everyday (Figure 4). Twenty patients (21.1%)
spent <30 minutes/sessions, while 33 patients (34.7%)
spent ≥60 minutes on each exercise session (Figure 5).
Furthermore, 26 patients (27.4%) did exercise less than
three times per week or spent less than 30 minutes per

Figure 2. Types of exercise performed.
6
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Figure 3. Intensity of exercise.

Figure 4. Frequency of exercise.
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Figure 5. Duration of exercise.

exercise session. There were not statistically different in
frequency and duration of exercise between male and
female patients. However, patients ≥65 years exercise more
frequent than their younger counterparts did (p=0.018).

3. Exercise Tolerance
Sixty percent of patients reported that they could
walk for more than an hour on level ground. Sixty-three
percent of patients reported that they could climb six or
more FOS, which implied ≥60 steps of stairs, at a time.

Discussions
According to guidelines from the Centers for
Disease Control and Prevention and the American
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College of Sports Medicine, patients are recommended
to do at least 30 minutes of moderate-intensity (≥3
METs) exercise on most, and preferably all, days of
the week.1,4,7 Furthermore, to maximize the benefits of
cardiac rehabilitation, long-term maintenance of regular
moderate-intensity exercise for least 12 weeks is
necessary.
Although the benefits of exercise are
acknowledged, compliance to the recommendations is
difficult.8 In USA, less than 25% of Americans could
achieve the recommended level of exercise.4 In our
study, 47%, 14%, and 21% of patients had less than the
recommended level of intensity, frequency, and duration
during exercising. Long-term maintenance of exercise
is not easy as well, especially when supervision is
withdrawn.8 Community-based exercise classes provide
regular, structured and supervised training programme.
However, only 3% of patients in the study worked out
at fitness centers. Scottish Intercollegiate Guidelines
Network (2002) also indicated that there is no restriction
on the nature of exercise performed by patient as long
as patients adhere to the recommendation.8 Therefore,
periodically review with patients their exercise pattern
and provide education and counseling is essential to
support patients' adherence to do exercise after
completion of Phase II CRP.3
Tai Chi and Qigong was the second most
common type of exercise (24.2%) performed by
patients. It is also becoming more popular in United
States. They are Chinese exercise practice involving
gentle movements of body as well as training of body,
breath, voice and mind. 9 According to Ainsworth
(2000), they were classified as moderate-intensity
(3 METs) aerobic exercise.6,9 Studies had documented
their benefits in many areas including elders, arthritis
patients, patients with cardiovascular disease, and
others with chronic illness.9 Therefore, the exercise
could be promoted to cardiac patients with associated
illness.
Metabolic equivalent (MET) is an absolute
scale in measuring the intensity of exercise. Its
classification was based on the physical effort of
healthy, middle-aged adults. Lee et al. (2003)
suggested that individual fitness levels should be
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considered when "moderate-" intensity exercise were
recommended. 2,3,10 In our study, more than one-half
of patients were aged over 65 years, and 47% of
patients performed light intensity exercise. During
review of their exercise pattern, elderly patients did
exercise at light-intensity might already
accomplished cardiac protection purpose. It is
therefore, necessary to consider patients' physical
fitness and tailored accordingly.
Sedentary lifestyles in cardiac patients should be
avoided. Findings indicated that even some form of
exercise provide certain benefits than non-exercise
group.11 For patients who did not exercise, their barriers
should be explored. Health care professionals should
discuss the benefits, risks, and opportunities about
exercise with them.8 In situation when patients' medical
conditions limited them from doing exercise, medical
treatment to stabilize their conditions should be given.
Their exercise recommendation should be revised and
customized to meet their conditions.12

Conclusions
Most of the patients (88.8%) could achieve
regular exercise habit after completion of Phase II CRP.
However, more than 25% of patients did not practice
exercise accordingly to the exercise guidelines.
Education and counselling in long-term maintenance
of exercise with appropriate frequency, duration and
intensity should be emphasised.

J HK Coll Cardiol, Vol 13
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Quality of Life in Patients with Atrial Fibrillation
PUI-YEE SIN, CHU-PAK LAU, HUNG-FAT TSE
From Cardiology Division, Department of Medicine, Queen Mary Hospital, The University of Hong Kong,
Hong Kong SAR
SIN ET AL.: Quality of Life in Patients with Atrial Fibrillation. Atrial fibrillation (AF) is one of the most
common symptomatic cardiac arrhythmia and is associated with substantial complications and health care
cost. Although AF is not an immediately life threatening disease, it is associated with significant symptoms,
and thus impairment of quality of life (QoL). Therefore, one of the major assessments for treatment outcome in
AF patients is improvement of QoL. Current available data do suggest that patients with AF have markedly
impairment of QoL compared to healthy controls and patients with other cardiovascular diseases. In the majority
of AF patients, rate or rhythm control appears to provide similar benefit on QoL. However, in highly symptomatic
AF patients, successful nonpharmacological rhythm-control might yield the largest improvement in QoL. Future
studies are required to compare QoL in different patient populations, different types of AF and different
therapeutic approaches in patients with AF. Furthermore, the development and validation of a more diseasespecific QoL instrument for AF can improve the measurement of health status in patients with AF. (J HK Coll
Cardiol 2005;13:10-15)
Atrial fibrillation, quality of life

Introduction
Atrial fibrillation (AF) is one of the most common
symptomatic cardiac arrhythmia and is associated with
substantial complications and health care cost.
Epidemiology studies have shown a prevalence of
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0.5% to 1% for AF in the general population.1,2 The
prevalence of AF increases with age with less than 1%
in those under 60 years of age and greater than 6% in
those aged 80 years or older.1 In Hong Kong, AF occurs
in 1.3% of healthy adults aged >65 years.3 In United
States, the median age of subjects with AF is 75 years,
with 70% between the ages of 65 and 85 years. 4
Furthermore, Framingham study have demonstrated that
AF is more common in men and has a 1.5-fold greater
risk of developing AF than women after adjustment for
age and predisposing conditions.2
AF is frequently associated with the presence of
underlying cardiovascular disorders. Prior studies in
Hong Kong had shown that hypertension (29%),
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artherosclerotic cardiovascular disease (25%) and
chronic rheumatic heart diseases (17%) accounted for
over 70% of the patients admitted into hospital with AF.5
Furthermore, heart failure is closely associated with AF.
In patients with heart failure, the prevalence of AF
increases from <10% in those with New York Heart
Association (NYHA) functional class I to approximately
50% in those with functional class IV. 6 Lone AF
describes situations in which no underlying or detectable
causes for AF could be identified, and is reported to
occur in 12-30% of patients with AF.7-9
The total mortality rate, which is largely due to
stroke, is approximately doubled in patients with AF
compared with patients in normal sinus rhythm.10,11 In
patients with rheumatic heart disease and AF, stroke
risk was increased 17-fold compared to age-matched
controls.12 The rate of ischemic stroke among patients
with non-rheumatic AF averages 5% per year, which is
2 to 7 times the rate for people without AF. 10
Furthermore, those patients with advancing age, prior
stroke, hypertension, diabetes or congestive heart failure
have a higher risk of stroke.11
As discussed above, considerable studies have
been performed to address the epidemiology and clinical
consequences of AF. Therefore, studies on the efficacy
of therapy in AF have been predominantly assessed by
morbidity and mortality measures. Although AF is not
an immediately life threatening disease, it is associated
with significant symptoms. Patients with AF have
symptoms that are highly likely attributable to the
arrhythmia itself, rather than accompanying
cardiovascular conditions. Therefore, one of the major
purposes for treatment of patients with AF is to relieve
symptoms and to improve quality of life (QoL). As a
recent, more interest has been developed on the
assessment of patient related issues, such as
improvement of symptoms and QoL, as objectives in
treating AF.13 This article reviews currently available
data on the assessment of QoL in patients with AF.

and infirmity but also the presence of physical, mental,
and social well-being, the issue of QoL has become
steadily more important in health care practice and
research.14 The World Health Organisation Quality of
Life Group defined QoL as an individual's perception
of their position in life in the context of the culture and
value systems in which they live and in relation to their
goals, expectations, standards and concerns.15 It is a
broad range of concept affected in a complex way by
the person's physical health, psychological state, level
of independence, social relationships, and their
relationships to salient features of their environment.
QoL is a multidimensional concept and no
universal definition exists. Campbell et al notions of
QoL encompass domains such as housing, employment,
standard of living and marriage, etc. 16 Economic,
political, cultural, and spiritual factors may affect overall
QoL, but are generally not considered to fall under the
purview of physicians and health care systems.17 In the
literature, the terms health-related QoL, QoL, health
status and functional status are often used
interchangeably. QoL is a broader concept while healthrelated QoL only includes aspects related to health only.
Five health concepts are inherent in health-related QoL
definition: physical health, mental health, social
functioning, physical and general well-being.18 Healthrelated QoL can be conceptualised as the physical,
psychological, and social domains of health which are
influenced by a person's perceptions experiences,
beliefs, expectations, and perceptions.19 The distinction
between health status and QoL is that health status refers
to the actual state of health but QoL measures the
perceived impact of health on life.20 Health status can
be assessed by objective as well as subjective methods
but QoL is always subjective. Functional status refers
to the physical, emotional and social consequences of
the disease process. It often includes measures that
assess performance of activities of daily living, such as
walking, eating or interacting with family.21

Definition of QoL

Assessment of QoL in Patients with AF

Since 1947, when the World Health Organization
defined health as being not only the absence of disease

Measurement of QoL is particularly relevant to
the management of AF as the one of the major goal of
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treatment is to relieve symptoms and improve QoL in
this chronic condition. There are several purposes to
evaluate QoL in patients with AF: 1) to select patients
for various treatment; 2) to determine the choice of
treatment; 3) to monitor patients progress; 4) to assess
the impact of complications; and 5) to use as an outcome
measure in research studies and clinical trials.
The instruments available to measure QoL can
be divided into either 1) generic instruments or
2) disease-specific instruments. Generic instruments are
usually broader measures of health status. They are used
in the general population to assess a wide range of
domains and can be applied to a variety of health states,
conditions, and diseases. They are usually not specific
to any particular disease and therefore are useful for
making comparisons between disease states. The
Medical Outcomes Study Short Form Health Survey
(SF-36) is currently the most widely validated generic
instrument.22-25 A generic instrument is often used in
combination with a disease-specific instrument which
is more sensitive to detect symptoms-related changes.
Disease-specific instruments focus on the domains most
relevant to the disease or condition under study and on
the characteristics of patients in whom the conditions
is most prevalent. The Symptom Checklist: Frequency
and Severity (SCL) is a disease-specific instrument
developed for patients with cardiac arrhythmias. 26
However, there is no disease specific QoL for patients
with AF.

The Medical Outcomes Study
Short Form Health Survey (SF-36)
The SF-36 is a widely validated generic measure
that has been used in estimating disease burden, such
as in conditions of arthritis, back pain, cancer, and
cardiovascular disease. It is useful for making
comparison with the general population. SF-36 is a
generic health scale with eight subscales of health
dimensions: physical function, role limitations due to
physical problems (role-physical), bodily pain, general
health, vitality, social functioning, role limitations due
to emotional problems (role-emotional), and mental
health. The scores in each of the eight subscales are

12

standardized from 0 to 100, and a higher scale scores
indicates better QoL. The SF-36 is commonly used
because there is a lot of evidence to support its
conceptual base, validity, reliability, psychometric
properties, sensitivity and responsiveness in many
different populations and patient groups.22-25 Internal
consistency reliability coefficients (Cronbach' alpha) on
all scales of the SF-36 exceed alpha of 0.8, except for
social functioning with alpha of 0.76.23 The use of the
SF-36 survey was validated across 24 diverse patient
groups and reported reliability coefficients with a range
of 0.65 to 0.94 across.24 The Chinese (HK) version of
the SF-36 health survey was the only health-related QoL
measure that has been both validated and normed on
Chinese adults in Hong Kong.25,27

Symptom Checklist: Frequency
and Severity (SCL)
The symptom checklist: frequency and severity
was specifically developed for patients with cardiac
arrhythmias.26 The checklist comprises 16 items that
are specific for arrhythmias, such as palpitations,
dyspnoea, dizziness, exercise intolerance, chest
discomfort and syncope, etc. Both the frequency and
severity of symptoms related to the arrhythmias are
quantified. Frequency is quantified from 0-4: "0" for
"Never"; "1" for "Rarely"; "2" for "Sometimes"; "3"
for "Often" and "4" for "Always". Severity is quantified
from 0-3: "1" for "Mild", "2" for "Moderate" and "3"
for "Extreme". The range of possible scores is 0-64 for
frequency and 0-48 for severity. Higher scores reflect
more symptomatic individuals.
The SCL is a disease-specific measure. Diseasespecific measures can be more responsive to changes
in patients' health because they highlight more relevant
manifestations of the illness and tailor their response
categories to a more relevant range of function than
generic measures.28 Berkowitsch et al investigated the
effects of catheter ablation on QoL in 60 patients with
AF, and analysed the dynamics of SCL and SF-36
parameters.29 The results of this study showed that SCL
is a more specific instrument for a measurement of the
procedure success or failure than SF-36.
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QoL in Patients with AF
Table 1 summarised the clinical studies on QoL
in patients with AF. In these studies, both patients with
paroxymal and chronic AF were included. Four studies
have compared the QoL in AF patients with a control
group30-32 or the general population.33 The results of these
studies have consistently demonstrated that patients with
paroxysmal and chronic AF,30-32 silent AF32 and newly
diagnosed AF33 have significantly poorer QoL than
control or general population as determined by SF-36.
Furthermore, AF patients had significantly impairment

of QoL as compared to patients with coronary artery
disease and similar to patients with heart failure.30
Among patients with AF, female patients reported
significantly poorer physical and functional health
compared to male patients.34 In the AFFIRM Study,
baseline SF-36 scores and total QoL index scores
were also lower in women and patients older than 65
years old. 35 Furthermore, patients with paroxysmal
AF who reported frequency arrhythmia recurrence
had more impairment of QoL compared to patients
with persistent and permanent AF.36 In patients with
persistent and permanent AF, their clinical courses

Table 1. Clinical Studies on QoL in Patients with AF
Reference

Patients (mean
age, years)
Dorian, et al, 152 paroxysmal AF
200030
patients (52±12)
vs. 47 controls
(54±14) vs. 69
patients with
coronary artery
diseases
van den
73 paroxysmal AF
Berg, et al, (54±13) vs. 180
age- and sex200131
matched controls

Savelieva,
154 AF patients
et al, 200132 (58±12) vs. 49
controls

Kang, et al,
200433

Types of
Objectives
AF
Paroxysmal Assess the impact
AF
of paroxysmal PAF
on QoL vs. control
and patients with
other cardiovascular
disease

QoL Instruments

SF-36, SCL,
Specific activity,
Illness intrusiveness,
University of Toronto
AF severity Scales

Paroxysmal To assess the impact SF-36
AF
of AF on QoL, and
to determine the
predictors of QoL
in AF patients
Chronic
AF-40%
Paroxysmal
AF-60%

81 patients with AF Newly
<3 months (mean diagnosed
age: 67)
AF

QoL in
symptomatic AF
patients were
compared with
silent AF patients
and controls

Main Findings

-

-

SF-36, SCL,
Modified Goldman
specific activity scale, illness intrusive
ratings

Compared QoL in SF-36, SCL
patients newly
diagnosed with AF
vs. general US
population

-

-

Paquette,
170 AF patients:
Chronic and Compared QoL in SF-36, SCL, Duke
et al, 200034 62 female (68±9)
paroxysmal male vs. female AF Activity Status
vs. 108 male (62±1) AF
patients
Index, University of
Toronto Atrial
Fibrillation Severity
Scale
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Patients with paroxysmal AF
reported significantly impaired
QoL compared to control and
patients with percutaneous
coronary intervention, but was
similar to patients with heart
failure or postinfarction.
AF patients had impaired QoL
in all SF-36 subscales except
the pain subscale.
Symptoms and autonomic
function were important
predictors of QoL.
Impaired QoL in all AF patients
compared to control group.
In patients with silent AF, most
SF-36 scale scores did not differ
much with normal subjects, but
the perception of general health
and the rating of global life
satisfaction was poorer.
Impaired QoL in patients with
newly diagnosed with AF vs.
general population.
Frequency and severity of
symptoms inversely related to
QoL.
Female AF patients had more
QoL impairment than male AF
patients.
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are more predictable with stable ventricular rate, and
have less impairment in QoL than patients with
paroxysmal AF. 37 However, in patients with
paroxysmal AF, the severity and frequency of AF
episodes were not predictive of QoL.30,31

Effect of Therapeutic Intervention
on QoL in Patients with AF
In regard to the treatment of AF, successful
restoration and maintenance of sinus rhythm are
conceptually expected to improve QoL, reduce the
morbidity and mortality. However, recent randomized
trials have failed to show any superiority of rhythm
control strategy, primarily pharmacological over rate
control plus anticoagulation strategy in term of quality
of life, stroke and mortality.38-41 In 716 patients included
in the AFFIRM QoL substudy, 42 there were no
significant difference in QoL score between patients
assigned to rate- and rhythm-control at all time points.
Furthermore, QoL scores improved in both group with
treatment, and were similar whether the actual rhythm
was sinus or AF.
The equivalent status of the two therapeutic
strategies may not be applicable to all patients with AF.
In these studies,38-41 the majority of patients were elderly
with relatively mild symptoms, had multiple risk factors
for stroke, but with only a small proportion with severe
heart failure. Attempts to improve QoL by restoring
sinus rhythm in these AF patients might not be
successful. 42 There are different subsets of patients,
both young and old, who are candidates for
maintenance of sinus rhythm,43 and may benefit from
nonpharmacological approaches including catheter
ablation,44,45 permanent cardiac pacing46,47 and surgical
procedure alone48 or in combination, in the prevention
of AF. In highly symptomatic AF patients, these
current available literatures do suggest that these
nonpharmacological provide the largest improvement
in QoL. However, the majority of studies on the effect
of nonpharmacological therapies on QoL in AF
patients are limited by small sample size, uncontrolled
studies without a control group on medical therapy
alone, relatively short duration of follow-up and use
of non-validated QoL instruments.
14

Conclusion
Assessment of QoL has become an important
clinical outcome measures in management of patients
with AF. Current available data do suggest that patients
with AF have markedly impairment of QoL compared
to healthy controls and patients with other
cardiovascular diseases. In the majority of AF patients,
rate or rhythm control appears to provide similar benefit
on QoL. However, in highly symptomatic AF patients,
successful nonpharmacological rhythm-control might
yield the largest improvement in QoL. Future studies
are required to compare QoL in different patient
populations, different types of AF and different
therapeutic approaches in patients with AF.
Furthermore, the development and validation of a more
disease-specific QoL instrument for AF can improve
the measurement of health status in patients with AF.
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From Cardiology Division, Department of Medicine, Queen Mary Hospital, The University of Hong Kong,
Hong Kong SAR
SIU ET AL.: Thyrotoxic Heart Disease. The close link between the thyroid gland and the heart has been well
recognized since the first description of thyrotoxicosis in nearly 200 years ago. Despite this well known
association, there have been only a few population based studies performed on thyrotoxic heart disease except
thyrotoxic atrial fibrillation. Even so, there has not been any consensus for the definition for "thyrotoxic heart
disease". For other cardiac manifestations of thyrotoxicosis including thyrotoxic cardiomyopathy and thyrotoxic
pulmonary hypertension, only occasion case reports can be found in the current medical literatures. Their
natural history, clinical course and outcomes are largely unknown. On the other hands, there is an enlarging
body of evidence suggesting a direct pathogenic role of thyrotoxicosis per se as the sole cause of these thyrotoxic
heart diseases. In this review, we briefly discuss the three cardiac consequences of thyrotoxicosis, namely
atrial fibrillation, congestive cardiac failure and pulmonary hypertension. (J HK Coll Cardiol 2005;13:16-20)
Atrial fibrillation, cardiac failure, thyrotoxicosis
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Introduction
Thyrotoxicosis is a common medical condition
with prevalence of 2 percents in female and 0.2-0.3
percent in male. 1 The close link between the thyroid
gland and the heart was evident since the first
description of thyrotoxicosis for nearly two hundred
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years ago. 2 Many of the clinical manifestations of
thyrotoxicosis are due to the ability of thyroid
hormone to alter cardiovascular hemodynamic.3 The
usual coined terms to describe the association of
thyrotoxicosis and its cardiac manifestations include
"thyrotoxic heart disease", "thyro-cardiac disease"
and "thyro-heart disease". Despite the frequent
appearances of these terms in medical literatures,
there has been no consensus of its definition. For
simplicity, we may define "thyrotoxic heart disease"
as the association between thyrotoxicosis and its
cardiovascular complications. In this review, we
briefly discuss the three cardiac consequences of
thyrotoxicosis, namely atrial fibrillation, congestive
cardiac failure and pulmonary hypertension.

April 2005

J HK Coll Cardiol, Vol 13

SIU ET AL.

Atrial fibrillation
Prevalence
Atrial fibrillation (AF) is the most well-known
cardiovascular complication in thyrotoxic patients and
its clinical importance often overshadows the most
common rhythm disturbance, sinus tachycardia in this
population. Atrial fibrillation occurs in 5 to 20 percent
of patients with thyrotoxicosis.4-8 On the other hands, as
many as 13 percent of patients with unexplained atrial
fibrillation have biochemical evidence of thyrotoxicosis.9
In these studies, they consistently showed that the
prevalence of atrial fibrillation increased with age in
thyrotoxic population as in general population. Also,
in one of the most frequently cited study by Sandler
and Wilson published nearly half century ago, the
authors observed that the prevalence of atrial fibrillation
was higher among thyrotoxic men than women.10 More
recently, Shimizu et al described the prevalence of atrial
fibrillation in a large cohort of 13,088 thyrotoxic patients
in Ito hospital in Tokyo.11 They showed that the annual
incidence of atrial fibrillation was only 1.7%, much
lower than previous studies. However, similar to
previous studies, the incidence of atrial fibrillation
increased with age and was higher in male thyrotoxic
subjects. Unfortunately, only age and sex were analyzed
in this particular study but other co-morbidities and
potential confounding factors had not been adjusted.

Mechanisms
In general, for atrial fibrillation to develop, three
basic components are required: 1) a specific triggers;
2) a suitable substrate; and 3) modifying factors.
Haissagurere et al. have demonstrated that a single source
of rapid impulses, mainly originating from the
pulmonary veins,12 is the majority source of trigger for
the initiation and maintenance of AF in patients with
paroxysmal AF. In thyrotoxic rat model, thyroid
hormone has been shown to increase automaticity and
enhance triggered activity of pulmonary vein which may
increase its arrhythmogenic activity similar to that
observed by Haissagurere group. 13 Besides, thyroid
hormone also modifies the electrophysiological
properties of the atrium: shortening the atrial action
potential duration and atrial refractory period, creating
substrate favor the maintenance of atrial fibrillation. In
J HK Coll Cardiol, Vol 13

addition, modifying factors particularly autonomic tone
also play contributory role in the pathogenesis of atrial
fibrillation in previous studies. Both parasympathetic
and sympathetic stimulation shorten the atrial
refractoriness which is associated with induction and
maintenance of AF.

Outcomes
It is usually assumed that successful treatment of
thyrotoxicosis often associates with reversion of sinus
rhythm spontaneously. However, there are only a few
studies in medical literatures providing information for
this issue. Nakazawa et al showed that 62% thyrotoxic
patients with atrial fibrillation had spontaneous sinus
conversion within the first 3 to 4 months after
euthyroidism, even without anti-arrhythmic agents in
1982.14 Also, atrial fibrillation is unlikely to revert to
sinus rhythm beyond this period without cardioversion.
For those thyrotoxic patients with persistent atrial
fibrillation after euthyroidism achieved, DC
cardioversion is highly effective for sinus conversion
(~90%) and sinus rhythm maintenance rates were
exceedingly high (56% at tenth year) compared to nonthyrotoxic atrial fibrillation population whom underwent
cardioversion.15
One of the most devastating consequences of
atrial fibrillation is the systemic thromboembolism
including stroke. However, whether thyrotoxic atrial
fibrillation population is at increased risk for systemic
thromboembolism has not been clearly evaluated for the
time being. Two retrospective studies, both were
conducted more 15 years ago, revealed a higher embolic
rate in those with atrial fibrillation than those in sinus
rhythm among thyrotoxic population.16,17 However, in
one of these two studies, age rather than the presence of
atrial fibrillation, was the main risk factor for
thromboembolism.16 So far, there is no large prospective
population study to confirm this observation.

Congestive Cardiac Failure
Although clinical heart failure can occasionally
happen in the setting of thyrotoxicosis, most patients
with clinical overt heart failure are simply because of
persistent sinus tachycardia or atrial fibrillation, their

April 2005

17

THYROTOXIC HEART DISEASE

left ventricular systolic function is usually normal. It is
understandable that for those patients with preserved left
ventricular function, the clinical congestive cardiac
failure may well be secondary to rapid atrial fibrillation
and possibly an element of diastolic dysfunction.
However, in the setting of atrial fibrillation, the
contribution of left ventricular diastolic dysfunction is
rather difficult to assess. It was for many years, assumed
that this condition was seen only in the presence of
underlying cardiovascular disease. In recent years,
occasional case reports and case series were found in
medical literatures, describing thyrotoxicosis as a cause
of "reversible" dilated cardiomyopathy.18-20 However,
there has been an emerging concept, introduced by
Levine and his coworkers, on the basis of their clinical
observations of patients in whom thyrotoxicosis was
the sole or principal factor leading to clinical overt heart
failure and cardiomyopathy.21,22 However, because of the
"rarity" of this clinical entity, the incidences of clinical
congestive cardiac failure and dilated cardiomyopathy
in thyrotoxic patients are not available in current medical
literatures. In addition, their nature, prognosis and
reversibility remained largely unknown.
In recent years, an enlarging body of knowledge
from both human and animal studies suggesting the
existence of the entity of "pure thyrotoxic dilated
cardiomyopathy". Substantial body of evidence indicates
that an excess thyroid hormone alone can cause cardiac
failure in a number of species.23 Forfar and associates
had assessed the effects of exercise on left ventricular
ejection fraction measured by radio-nucleotide
ventriculography in human cases with spontaneous
uncomplicated hyperthyroidism.24 They found that in
hyperthyroid state, patients exhibited a high left
ventricular ejection fraction at rest but paradoxically,
the EF fell significant during exercise. At the same
workload and heart rate during euthyroid state, patients
restored a normal rise in left ventricular ejection fraction
upon exercise. These findings suggested hyperthyroid
state may result in the poor cardiac reserve despite
normal resting EF.
Changes in thyroid hormone status influence
cardiac action by three different routes: 1) thyroid
hormone exerts a direct effect on cardiac myocytes
primarily by binding to nuclear T3 receptors influencing
cardiac gene expression 2) thyroid hormone increases
18

the sensitivity of the sympathetic system in the
hyperthyroid heart and 3) thyroid hormone leads to
hemodynamic alterations in the periphery which results
in increased cardiac filling and modification of cardiac
contraction.
Most of the molecular and cellular mechanisms
responsible for cardiovascular effects by thyroid
hormone exert through both genomic and nongenomic
effects on cardiac myocytes (Figure 1). The genomic
effects of the thyroid hormone are mediated by the
transcriptional activation or repression of specific target
genes that encode both structural and functional proteins.
Once in the cardiac myocytes, T3 enters the nucleus and
interacts with specific transcriptional activators (nuclear
receptor α1) or repressors (nuclear receptor α2).
Occupancy of these receptors by T3, in combination with
recruited cofactors, allows the thyroid hormone-receptor
complex to bind (nuclear receptor α1) or release (nuclear
receptor α2) specific sequences of DNA (thyroidresponsive element, TRE), that, in turn, by acting as cisor trans-regulators, modify the rate transcription of
specific target gene. 25 Figure 1 summarized
transcriptional change in difference gene expression. One
example is that thyroid hormone altering the gene
expression in cardiac myocytes leads to changes in the
proportion of myosin heavy-chain protein from beta to
alpha, thereby increasing myosin V1 and decreasing
myosin V3 isozyme levels which may result in relatively
ineffective use of energy in ventricular myocardium.
On the other hands, hemodynamic changes
secondary to peripheral vascular effect of thyroid
hormone may further complicate the picture.6,26 As a
result of thyroid hormone on the heart and peripheral
vasculature, there is an increase in heart rate, blood
volume, left ventricular stoke volume, ejection fraction
and cardiac output. Peripheral vasodilatation occurs as
a result of rapid utilization of oxygen, increased
metabolic end products, and induction of arterial smooth
muscle cell relaxation by thyroid hormone directly.
Vasodilatation results in a decrease in systemic vascular
resistance by an average of 50-60%. The decrease in
systemic vascular resistance plays a central role in the
hyperthyroid hemodynamic changes. Vasodilatation and
lack of increase in renal blood flow cause a decrease in
renal perfusion pressure and an activation of the renninangiotensin system, thus increasing sodium reabsorption
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Figure 1. Genomic effects of thyroid hormone (T3) on cardiomyocytes NR, Triiodothyronine
nuclear receptor; TRE, thyroid hormone responsive element.

and thus the blood volume. This may at the end increase
the cardiac output by 2-3 folds.
It seems that in the hyperthyroid state, enormous
changes in the loading situation (both pre-load and afterload) together with structural changes of the cardiac
myocytes which may lead to decrease cardiac reserves,
in susceptible individuals, these factors may at the end
of days lead to the development of clinical overt cardiac
failure in the absence of underlying heart disease.

Pulmonary Hypertension
Since early 1980s, thyrotoxicosis has been
increasingly recognized as a rare cause of pulmonary
hypertension as accumulating case reports and case
series had been published describing this association.27-30
In most series, pulmonary arterial hypertension were
defined as the peak pulmonary systolic pressure
>35 mmHg and nearly exclusively derived with
echocardiographic technique. Similar to congestive
cardiac failure, there has no been any large prospective
population based study for this population therefore
J HK Coll Cardiol, Vol 13

incidence, nature, prognosis and reversibility of
thyrotoxic pulmonary hypertension remained largely
obscure.
Two possible mechanisms have been put forwards
to explain this association: 1) elevation of pulmonary
vascular resistance and 2) high cardiac output in
thyrotoxic state. It has been shown that there was a higher
prevalence of positive anti-thyroglobulin antibody
among thyrotoxic patients with isolated pulmonary
hypertension (8-folds) than in the general population.31
This observation leads to suggestion of possible
autoimmune phenomenon similar to primary pulmonary
hypertension, resulted in endothelial and vascular
damage in thyrotoxic pulmonary hypertension. However,
in the cases described by Cohen32 and Eleftheriadis,33
their patients presented with pulmonary hypertension
and frank right heart failure, initially thought to be
primary pulmonary hypertension but eventually found
to be a case of thyrotoxic pulmonary hypertension. The
interesting point is that in both cases, the pulmonary
pressure fell back to normal after euthyroidism achieved.
This makes the possibility of autoimmune process as a
cause of pulmonary vasculature damage and pulmonary

April 2005

19

THYROTOXIC HEART DISEASE

hypertension rather remote. Recently, a prospective
Doppler echocardiographic study further confirmed the
reversibility of pulmonary hypertension in
thyrotoxicosis population.34 In a mean follow-up time
of 14±8 months, 33 thyrotoxic patients with pulmonary
hypertension had significant drop in pulmonary artery
systolic pressure after euthyroidism. However, it
remains obscure whether the thyroid hormone exerts
its effect directly on the pulmonary vasculature or the
increase in cardiac output in thyrotoxic state leading to
the elevation of pulmonary artery pressure, in which
both may be normalized after euthyroidism.

Summary
The intimate relationship of thyroid gland and the
heart can aggravate pre-existing heart disease or even
lead to thyrotoxic heart diseases including atrial
fibrillation, congestive cardiac failure, cardiomyopathy
and pulmonary hypertension. Despite well-recognized
in clinical practice, many essential clinical information
including the epidemiology, outcome and management
strategies, have not been fully elucidated.

References
1. Tunbridge WM, Evered DC, Hall R, et al. The spectrum of
thyroid disease in a community: the Whickham survey. Clin
Endocrinol (Oxf) 1977;7:481-93.
2. Parry CH. Collections from the unpublished medical writings of
the late Caleb Hiller Parry ii, 111-123. London : Underwoods,1825.
3. Klein I. Thyroid hormone and the cardiovascular system. Am
J Med 1990;88:631-7.
4. Woeber KA. Thyrotoxicosis and the heart. N Engl J Med 1992;
327:94-8.
5. Polikar R, Burger AG, Scherrer U, et al. The thyroid and the
heart. Circulation 1993;87:1435-41.
6. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular
system. N Engl J Med 2001;344:501-9.
7. Weetman AP. Graves' disease. N Engl J Med 2000;343:1236-48.
8. Klein I, Ojamaa K. Thyrotoxicosis and the heart. Endocrinol
Metab Clin North Am 1998;27:51-62.
9. Forfar JC, Miller HC, Toft AD. Occult thyrotoxicosis: a
correctable cause of "idiopathic" atrial fibrillation. Am J Cardiol
1979;44:9-12.
10. Sandler G, Wilson GM. The nature and prognosis of heart
disease in thyrotoxicosis. A review of 150 patients treated with
131 I. Q J Med 1959;28:347-69.
11. Shimizu T, Koide S, Noh JY, et al. Hyperthyroidism and the
management of atrial fibrillation. Thyroid 2002;12:489-93.

20

12. Haissaguerre M, Jais P, Shah DC, et al. Spontaneous initiation
of atrial fibrillation by ectopic beats originating in the
pulmonary veins. N Engl J Med 1998;339:659-66.
13. Chen YC, Chen SA, Chen YJ, et al. Effects of thyroid hormone
on the arrhythmogenic activity of pulmonary vein
cardiomyocytes. J Am Coll Cardiol 2002;39:366-72.
14. Nakazawa HK, Sakurai K, Hamada N, et al. Management of
atrial fibrillation in the post-thyrotoxic state. Am J Med 1982;
72:903-6.
15. Shimizu T, Koide S, Noh JY, et al. Hyperthyroidism and the
management of atrial fibrillation. Thyroid 2002;12:489-93.
16. PPetersen P, Hansen JM. Stroke in thyrotoxicosis with atrial
fibrillation. Stroke 1988;19:15-8.
17. Bar-Sela S, Ehrenfeld M, Eliakim M. Arterial embolism in
thyrotoxicosis with atrial fibrillation. Arch Intern Med 1981;
141:1191-2.
18. Magner JA, Clark W, Allenby P. Congestive heart failure and
sudden death in a young woman with thyrotoxicosis. West J
Med 1988;149:86-91.
19. Fiorilli R, Del Prete G, Fasano ML, et al. Dilated thyrotoxic
cardiomyopathy. Ital Heart J Suppl 2000;1:931-4.
20. Yu YH, Bilezikian JP. Tachycardia-induced cardiomyopathy
secondary to thyrotoxicosis: a young man with previously
unrecognized Graves' disease. Thyroid 2000;10:923-7.
21. Levine SA, Sturge CC. Hyperthyroidism masked as heart
disease. Boston Med Surg J 1924;190:233-47.
22. Likoff WB, Levine SA. Thyrotoxicosis as the sole cause of
heart failure. Am J Med Sci 1943;206:425-34.
23. Ikram H. The nature and prognosis of thyrotoxic heart disease.
Q J Med 1985;54:19-28.
24. Forfar JC, Muir AL, Sawers SA, et al. Abnormal left ventricular
function in hyperthyroidism: evidence for a possible reversible
cardiomyopathy. N Engl J Med 1982;307:1165-70.
25. Brent GA. The molecular basis of thyroid hormone action.
N Engl J Med 1994;331:847-53.
26. Grattinger JS, Muenster JJ, Selverstone LA, et al. A correlation
of clinical and hemodynamic studies in patients with
hyperthyroidism with and without congestive heart failure.
J Clin Invest 1959;38:1316-27.
27. Shimazaki M, Mitsuhashi T, Hasegawa K. Idiopathic pulmonary
hypertension associated with hyperthyroidism--an autopsy case.
Nippon Rinsho 1980;38:1783-6.
28. Thurnheer R, Jenni R, Russi EW, et al. Hyperthyroidism and
pulmonary hypertension. J Intern Med 1997;242:185-8.
29. Yazar A, Doven O, Atis S, et al. Systolic pulmonary artery
pressure and serum uric acid levels in patients with
hyperthyroidism. Arch Med Res 2003;34:35-40.
30. Chu JW, Kao PN, Faul JL, et al. High prevalence of autoimmune
thyroid disease in pulmonary arterial hypertension. Chest 2002;
122:1668-73.
31. Yanai-Landau H, Amital H, Bar-Dayan Y, et al. Autoimmune
aspects of primary pulmonary hypertension. Pathobiology 1995;
63:71-5.
32. Cohen J, Schattner A. Right heart failure and hyperthyroidism:
a neglected presentation. Am J Med 2003;115:76-7.
33. Eleftheriadis D, Fourla E, Eleftheriadis N, et al. Hidden
hyperthyroidism in a young male patient. Int J Cardiol 2003;
89(2-3):313-4.
34. Merce J, Ferras S, Oltra C, et al. Cardiovascular abnormalities
in hyperthyroidism: a prospective Doppler echocardiographic
study. Am J Med 2005;118:126-31.

April 2005

J HK Coll Cardiol, Vol 13

